Showing results (61-70 of 115) with videos related to

Sort By:
Pageof 12
Clinical and Molecular Hepatology|March 11, 2025
Molecular Classification of Hepatocellular Carcinoma based on Zoned Metabolic Feature and Oncogenic Signaling PathwayTomoko Aoki, Naoshi Nishida, Yutaka Kurebayashi, et al.
European Journal of Gastroenterology & Hepatology|March 2, 2018
Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological responseNatsuko Kobayashi, Hiroko Iijima, Toshifumi Tada, et al.
Liver Cancer|October 30, 2023
Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept StudyMasatoshi Kudo, Tomoko Aoki, Kazuomi Ueshima, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 19, 2019
Liver fibrosis markers as assessed by ultrasound elastography and serum samples: A large comparative study in hepatitis virus B and C liver diseasesTakashi Nishimura, Hiroko Iijima, Hiroki Nishikawa, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 21, 2026
Prospective Study of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Based on Hepatobiliary Phase of Gd-EOB-DTPA-MRITomoko Aoki, Masatoshi Kudo, Kazuomi Ueshima, et al.
Ultrasound in Medicine & Biology|July 7, 2019
Usefulness of Attenuation Imaging with an Ultrasound Scanner for the Evaluation of Hepatic SteatosisToshifumi Tada, Hiroko Iijima, Natsuko Kobayashi, et al.
Journal of Gastroenterology|March 7, 2025
Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept studyTomoko Aoki, Masatoshi Kudo, Naoshi Nishida, et al.
Liver Cancer|January 2, 2023
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT StudyAndrea Casadei-Gardini, Margherita Rimini, Masatoshi Kudo, et al.
Scientific Reports|August 18, 2021
Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective studyAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|January 29, 2026
Effect of Butyrate-Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and TremelimumabKazuhiro Nouso, Akiko Wakuta, Shohei Shiota, et al.
Pageof 12